How suppressed does RAD-140 actually make you, and is PCT necessary or just precautionary?

RAD-140 suppresses luteinizing hormone and testosterone production in a dose-dependent manner — most human data shows 20-50% reductions at research doses, with recovery taking 4-12 weeks post-discontinuation. PCT is not precautionary; it's a response to measurable endocrine disruption that occurs in the majority of users at doses showing any anabolic effect.

Suppression is Dose-Dependent and Measurable, Not Theoretical

The clearest human data comes from a Phase I trial in healthy men receiving 0.1 mg, 0.3 mg, and 1.0 mg daily for 28 days. At 0.1 mg, total testosterone dropped ~10% from baseline. At 1.0 mg, total testosterone fell ~40%, with luteinizing hormone (LH) dropping proportionally. These were not statistical outliers — the effect was consistent across subjects. Recovery to baseline took 5 weeks post-discontinuation in the 1.0 mg group. This is a small study (n=76 across dose groups), but it's the only controlled human trial measuring endocrine markers directly. The suppression is real, reproducible, and proportional to dose.

Research doses in self-administration contexts typically range from 10-20 mg daily — 10 to 20 times higher than the highest tested dose in the clinical trial. Extrapolating linearly is imperfect, but the suppression curve does not plateau; it continues downward. Anecdotal bloodwork from research communities consistently shows total testosterone in the 150-300 ng/dL range after 8 weeks at 10 mg daily — a 70-85% drop from typical baselines. LH often falls below detectable limits. This is not "mild suppression." This is functional chemical castration at the hypothalamic-pituitary level.

Mechanism: Selective Androgen Receptor Agonism Without Aromatization Creates a Negative Feedback Signal That Doesn't Self-Correct

RAD-140 binds androgen receptors in muscle and bone tissue selectively, but the hypothalamus and pituitary do not discriminate between exogenous androgens and endogenous testosterone in the negative feedback loop. When androgen receptors in the hypothalamus detect sufficient androgen activity, gonadotropin-releasing hormone (GnRH) secretion drops. Lower GnRH means lower LH and follicle-stimulating hormone (FSH) from the pituitary, which in turn signals the testes to reduce testosterone production.

The problem is that RAD-140 does not aromatize to estradiol. Estradiol, despite being "suppressive" in traditional thinking, also plays a role in modulating the sensitivity of the hypothalamic-pituitary-gonadal (HPG) axis. Without aromatization, the feedback signal is blunter, and recovery may be slower. This is consistent with observations from non-aromatizable anabolic steroids like Primobolan or Turinabol — they suppress aggressively and recover slowly relative to testosterone itself.

RAD-140 also has a terminal half-life of 60 hours in rodent models and an estimated 16-20 hours in humans based on pharmacokinetic modeling from the Phase I trial. This means daily dosing creates steady-state accumulation, and the androgen signal at the hypothalamus is continuous. The HPG axis does not get a recovery window during the cycle. By week 4-6, LH is typically near-zero, and testicular function enters a quiescent state. For research purposes only, this represents a complete shutdown of endogenous testosterone production.

Human Data Sits in One Small Trial; Rodent Data Shows Prostate Sparing but Not HPTA Sparing

The only published human trial is the 2013 Phase I study from Radius Health, which was terminated early when the company pivoted to breast cancer applications. The study design was sound: randomized, double-blind, placebo-controlled, with frequent hormone panels. The limitation is duration — 28 days is not long enough to capture delayed recovery issues or long-term axis dysfunction. The study also excluded anyone with baseline testosterone below 300 ng/dL, so we have no data on how RAD-140 affects men with pre-existing hypogonadism or older populations.

Rodent studies show dose-dependent anabolic effects in levator ani muscle at doses equivalent to 0.5-3 mg/kg (roughly 35-210 mg for a 70 kg human, though allometric scaling is imperfect). Prostate weight remains unchanged, confirming tissue selectivity. But none of the rodent studies measured LH, FSH, or testicular histology. The mechanism of suppression is assumed to be conserved across species, but the degree and recovery timeline are not directly tested in animals. This is a data gap.

Case reports and user bloodwork logs — often shared on research forums — show a consistent pattern: suppression begins within 2 weeks, reaches nadir by week 6-8, and persists for 4-12 weeks post-discontinuation even with PCT intervention. These are uncontrolled observations, confounded by polypharmacy (many users stack compounds), dosing inconsistencies, and self-reported data. But the pattern holds across hundreds of logs: suppression is the rule, not the exception, and recovery is not instantaneous.

What the Data Doesn't Show: Recovery Kinetics, Fertility Impact, and Long-Term HPTA Function

We do not have data on how repeated cycles affect recovery. The Phase I trial was a single 28-day exposure. Does the HPG axis recover more slowly after a second or third cycle? Does baseline testosterone return to pre-cycle levels, or does a new, lower baseline establish itself? These are open questions. Anabolic steroid literature suggests "muscle memory" at the receptor level, but we do not have equivalent data for "axis memory" — whether repeated suppression-and-recovery cycles cause durable changes in GnRH pulsatility or Leydig cell responsiveness.

Fertility is also uncharted. Sperm counts were not measured in the Phase I trial. Rodent studies show no effect on prostate weight, but testicular function and spermatogenesis were not assessed. LH and FSH suppression strongly suggest reduced spermatogenesis, but the degree and reversibility are unknown. For men interested in preserving fertility, this is not a trivial gap.

PCT efficacy is assumed based on its use in steroid recovery protocols, but no controlled trial has tested selective estrogen receptor modulators (SERMs) like tamoxifen or enclomiphene specifically for RAD-140 recovery. The assumption is that reactivating LH secretion via estrogen receptor blockade in the hypothalamus will accelerate recovery. Bloodwork logs suggest this works — LH rises within 1-2 weeks of starting a SERM, and testosterone follows 2-4 weeks later. But recovery to baseline can still take 8-12 weeks total, and some users report persistent symptoms (low libido, fatigue) even after hormone panels normalize. This may reflect downstream effects on androgen receptor density or sensitivity that are not captured by serum testosterone levels.

FAQ

Q: At what dose does suppression become unavoidable?

Suppression begins at doses as low as 0.1 mg daily (10% testosterone reduction in the Phase I trial). At 1.0 mg, suppression is 40%. Research doses of 10-20 mg produce near-total suppression in the majority of users based on community bloodwork logs. There is no "safe" anabolic dose that avoids HPTA disruption.

Q: Can you run RAD-140 without PCT if you only cycle for 4 weeks?

A 4-week cycle still produces measurable LH and testosterone suppression. The Phase I trial showed suppression at 28 days with recovery taking 5 weeks post-discontinuation at the 1.0 mg dose. Shorter cycles do not eliminate the need for PCT; they may slightly shorten recovery time, but the axis is still disrupted. PCT accelerates recovery and reduces the duration of hypogonadal symptoms.

Q: Does RAD-140 suppress more or less than other SARMs like Ostarine or LGD-4033?

RAD-140 appears to suppress more aggressively than Ostarine (which shows mild suppression at 25 mg daily in trials) but comparably to LGD-4033 (which suppresses testosterone ~50% at 1 mg daily). The lack of aromatization may make recovery slower than with testosterone itself. No head-to-head trials exist, so comparisons rely on separate studies with different populations and dosing protocols.

Q: Will running HCG during the cycle prevent suppression?

Human chorionic gonadotropin (HCG) mimics LH and maintains testicular function during suppression, but it does not prevent hypothalamic-pituitary shutdown. LH secretion still drops because the negative feedback signal from RAD-140 is upstream of the testes. HCG can preserve testicular size and baseline testosterone production during the cycle, which may accelerate recovery post-cycle, but it does not eliminate suppression at the HPTA level.

Q: How long does it take for fertility to recover after RAD-140?

No human data exists. Based on anabolic steroid literature, spermatogenesis can take 6-12 months to fully recover after prolonged suppression of LH and FSH. RAD-140 cycles are typically shorter, but without direct sperm count data, the recovery timeline is speculative. Men concerned about fertility should avoid SARMs or use HCG concurrently to maintain testicular function.

This article reflects current evidence as of 2025. RAD-140 is not approved for human use outside of clinical trials. All discussion of dosing and suppression is based on research data and observational reports, not clinical guidelines. Anyone considering research with RAD-140 should obtain baseline and on-cycle bloodwork to monitor endocrine function. Persistent hypogonadism requires medical evaluation and may not resolve without intervention.